RPL17 and neoplasm: In line with this idea, anti-PD-1 mAb has been shown to promote the emergence of new clonotypes of tumor-specific CD8+ T cells in preclinical models and patient tumor biopsies (Liu et al., 2022; Nagasaki et al., 2022; Wu et al., 2020; Yost et al., 2019).